Table 1 shows data from a set of 36 clinical trials including 13 on NSCLC and 6 on other cancers treated with PD-1/PD-L1 drugs, 5 on cancer patients treated with anti-CTLA-4 drugs, 2 treated with anti-MUC1 drugs, and 10 with anti-VEGF drugs. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.